UT MD Anderson Presentations at SSO

Pre-course: Surgical clinical trials primer: Designing your study (non-CME)

8 a.m.–12:30 p.m.
102AB

Why trials fail: Beyond just sample size
10:45–11:05 a.m.
Faculty: Beth Helmink, M.D., Ph.D.

Breast great debate

8:55–9:55 a.m.
301D

Debate #1: When clinical trials answer only one piece of the puzzle: How should multidisciplinary teams implement partial evidence in locoregional breast cancer management — Con
9:08–9:18 a.m.
Faculty: Simona Shaitelman, M.D.

Debate #1: Rebuttal — Con
9:20–9:22 a.m.
Faculty: Simona Shaitelman, M.D.

Debate # 2: Should pCR allow us to omit surgery? — Pro
9:24–9:31 a.m.
Faculty: Helen Johnson, M.D.

Debate # 2: Rebuttal — Pro
9:39–9:40 a.m.
Faculty: Helen Johnson, M.D.

HPB great debate: Histotripsy for liver malignancies: Breakthrough or hype?

8:55–9:55 a.m.
301A
Moderator: Hop Tran Cao, M.D.

Poster park showcase

10–10:30 a.m.
HUB Poster Park

PPS8. Advanced clinical T category and high tumor grade independently predict worse survival among rectal cancer patients undergoing organ preservation
Presenter: Stephanie Keeling, M.D.

PPS11. Empty pelvis syndrome after beyond total mesorectal excision (bTME) for rectal cancer: Impact of surgical complexity and flap reconstruction
Presenter: Jessica Lie, M.D.

PPS16. Risk of ovarian metastasis in colorectal cancer-related carcinomatosis
Presenter: Ryan Morgan, M.D.

PPS17. Predicting regional lymph node metastasis in goblet cell adenocarcinoma of the appendix using an internally validated model: Can a right hemicolectomy be omitted?
Presenter: Sara Ginzberg, M.D.

PPS18. Evaluating peritoneal washing supernatant NGS integration to inform staging of peritoneal metastases
Presenter: Taylor Neilson, M.D.

2025 American Thyroid Association differentiated thyroid cancer guidelines: What is new? A surgical summary

10:30 a.m.–12 p.m.
105A-C
Moderator: Sarah Fisher, M.D.

Panel with case discussions to facilitate real-world application of the guidelines
11:17–11:57 a.m.
Faculty: Elizabeth Grubbs, M.D.

Abstract presentations: Breast I

10:30 a.m.–12 p.m.
301A

P8. Primary breast angiosarcoma: Clinicopathologic features and oncologic outcomes
11:21–11:28 a.m.
Presenter: Rick Vavolizza, M.D.

Abstract presentations: PSM

1:55–3:25 p.m.
301A
Moderator: Beth Helmink, M.D., Ph.D.

Early-onset colorectal cancer: Epidemiology, genetics, and evolving management (non-CME)

4–5 p.m.
HUB Theater

Screening, prevention, and future directions in early-onset colorectal cancer
4:36–4:47 p.m.
Faculty: Nancy You, M.D.

Management across the pancreatic adenocarcinoma continuum: From precursors to metastases

8–9:30 a.m.
301D

Oligometastases: Whether treatment should be expanded to surgery
8:47–9:02 a.m.
Faculty: Matthew Katz, M.D.

Patient-centered rectal cancer care

8–9:30 a.m.
105A-C
Moderator: Josh Smith, M.D., Ph.D.

Sequencing — chemotherapy or radiation first for LARC? And why?
8:27–8:39 a.m.
Faculty: Nancy You, M.D.

SSO awards assembly

10:20–10:50 a.m.
301A

Charles M. Balch Distinguished Service Award
10:20–10:30 a.m.
Recipient: Peter Pisters, M.D.

Bridging the gap: Developing APPs from new hire to independent practitioners in surgical oncology (non-CME)

1–2 p.m.
HUB Theater
Moderator: Steven Wei, Ed.D.

Expanding impact: APP transition to independent practice: APP role utilization and how to optimize success through APP independent practice clinics
1:25–1:35 p.m.
Faculty: Rae Reynolds, Ph.D.

Great debate: Controversies in the management of gastroesophageal junction (GEJ) cancers

2:35–3:35 p.m.
301D

Debate #2: Surgery should not be omitted
3:17–3:27 p.m.
Faculty: Brian Badgwell, M.D.

Debate #2: Rebuttal — Surgery should not be omitted
3:30–3:33 p.m.
Faculty: Brian Badgwell, M.D.

Abstract presentations: Quality/disparities

2:35–3:35 p.m.
105A-C

P88. Prospective evaluation of safety and patient satisfaction with apixaban versus low molecular weight heparin for extended prophylaxis after cancer surgery
3:26–3:33 p.m.
Presenter: Alexandra Adams, M.D.

Poster park showcase

3:40–4:10 p.m.
HUB Poster Park

PPS38. Circulating tumor DNA dynamics in neoadjuvant therapy response: A prospective study in inflammatory breast cancer patients
Presenter: Megan McClanahan, M.D.

HUB zone presentations: Breast podcast recap: Invasive lobular carcinoma (Non-CME)

3:45–4:05 p.m.
Breast/Endocrine HUB Zone
Moderator: Taiwo Adesoye, M.D.

HUB zone presentations: Trial in progress: Immuno-oncology (Non-CME)

3:45–4:05 p.m.
Immuno-Oncology HUB Zone

TIP3. A prospective feasibility study using preoperative ctDNA to tailor neoadjuvant chemotherapy for patients with colorectal or appendiceal adenocarcinoma
3:55–3:59 p.m.
Presenter: Ryan Morgan, M.D.

HUB zone presentations: Trial in progress: Pan-tumor (Non-CME)

3:45–4:05 p.m.
Pan-Tumor HUB Zone

TIP6. Metronidazole to optimize the microbiome of patients with rectal adenocarcinoma undergoing neoadjuvant therapy: protocol for the phase II MONARCH trial
3:51–3:55 p.m.
Presenter: Laurence Diggs, M.D.

Colorectal great debates

4:15–5:15 p.m.
301D
Moderator: Ramy Behman, M.D., Ph.D.

Abstract presentations: Breast II

8:30–10 a.m.
301D

P112. Clipped node pathology as a guide for limited axillary surgery in occult breast cancer
9:49–9:56 a.m.
Presenter: Courtney Lattimore, M.D.

ctDNA in GI surgical oncology — game changer or prognostic gimmick?

10:30 a.m.–12 p.m.
101A-C

Clinical implications of ctDNA in locoregional colorectal cancer
10:35–10:47 a.m.
Faculty: Nancy You, M.D.

Abstract presentations: Top-rated videos

10:30 a.m.–12 p.m.
301D

V2. Robotic proximal gastrectomy with double tract reconstruction and distal pancreatectomy with splenectomy for gastroesophageal junction tumor
10:40–10:49 a.m.
Presenter: Anneliese Hierl, M.D.